Wedbush Rates Immunome (IMNM) buy, $31 Price Target
Wedbush reiterates a buy rating for Immunome, setting a target price of $31 as shares trade at $18.36, a 68.85% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Wedbush rated Immunome, Inc. ($IMNM) "buy" with a $31 price target on June 12, 2026.
Since the rating, $IMNM is up 4.3% after 1 week, up 24.1% after 1 month and down 10.4% to date (from the $18.38 close on Jun 12, 2026).
IMNM
Immunome, Inc.
Key Points
- On June 12, 2026, Wedbush reiterated its buy rating on Immunome, Inc. (IMNM), maintaining a price target of $31.00.
- Currently, Immunome's shares are priced at $18.36, significantly below its 52-week high of $30.06, suggesting potential upside.
- Analysts have a consensus strong buy rating for Immunome, with a mean price target of $36.00 based on 14 opinions.
Get $IMNM trade alerts by text
We text you when insiders, Congress or big funds trade $IMNM. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Immunome, Inc. alert may contain errors. Disclosures
Wedbush Reiterates Buy Rating
On June 12, 2026, Wedbush reiterated its buy rating on Immunome, Inc. (IMNM) on the NasdaqCM, setting a price target of $31.00. The stock is currently trading at $18.36, which is well below its 52-week high of $30.06.
Analysts Set New Price Targets
Wedbush has kept its target price unchanged at $31.00. The firm sees potential in Immunome as it continues to develop its pipeline of oncology therapeutics. This rating follows a series of positive analyst actions earlier this year, reflecting confidence in the company's prospects.
Other Analyst Ratings
Immunome has received various opinions from other analysts recently. On October 16, 2026, William Blair initiated coverage with an outperform rating. Stifel also initiated coverage on October 1, 2026, with a hold rating and a target price of $24. Alliance Global Partners rated the stock as a buy with a target of $32.00 on September 21, 2026. These ratings contribute to a strong consensus among analysts, which currently stands at a strong buy with a mean price target of $36.00.
Stock Performance Context
Immunome's shares are currently trading at $18.36, significantly lower than the 52-week high of $30.06. The stock also trades below its 50-day moving average of $25.30, suggesting it may be undervalued at this point. Investors may want to watch for any upcoming developments that could influence the stock's price.
$IMNM price target
Immunome, Inc. daily closes and this analyst's $31 target. Not advice.
Recent Insider Activity
On June 25, 2026, Robert Lechleider, the Chief Medical Officer, purchased 55,000 shares at an average price of $8.73, valued at approximately $480,150. This transaction may indicate confidence in the company's future performance. Interestingly, Lechleider also sold 55,000 shares on the same day, but the details on that transaction's price were not disclosed.
What IMNM Does
Immunome, Inc. is a biotechnology company based in Bothell, Washington. It focuses on developing antibody-drug conjugates and other therapies for cancer treatment. The company's ongoing clinical trials and product pipeline are key factors in its growth potential, which analysts are optimistic about.
What's Ahead for IMNM
Investors should keep an eye on Immunome's next earnings report scheduled for November 5, 2026. As a reminder, the recent analyst ratings and insider transactions reflect past performance and may not fully represent current positions. The reiteration of Wedbush's buy rating aligns with a positive outlook from several analysts in the sector.
Related Filing Alerts
Source: Wedbush's rating change on $IMNM (Jun 12, 2026). Written by software, not financial advice. How we make alerts